关键词: Antiemesis CINV Cancer chemotherapy Clinical practice guidelines Nausea Vomiting

Mesh : Humans Japan Medical Oncology / standards Antiemetics / therapeutic use Vomiting / prevention & control drug therapy Neoplasms / drug therapy Antineoplastic Agents / therapeutic use Societies, Medical Nausea / prevention & control drug therapy

来  源:   DOI:10.1007/s10147-024-02535-x   PDF(Pubmed)

Abstract:
BACKGROUND: The Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis 2023 was extensively revised to reflect the latest advances in antineoplastic agents, antiemetics, and antineoplastic regimens. This update provides new evidence on the efficacy of antiemetic regimens.
METHODS: Guided by the Minds Clinical Practice Guideline Development Manual of 2017, a rigorous approach was used to update the guidelines; a thorough literature search was conducted from January 1, 1990, to December 31, 2020.
RESULTS: Comprehensive process resulted in the creation of 13 background questions (BQs), 12 clinical questions (CQs), and three future research questions (FQs). Moreover, the emetic risk classification was also updated.
CONCLUSIONS: The primary goal of the present guidelines is to provide comprehensive information and facilitate informed decision-making, regarding antiemetic therapy, for both patients and healthcare providers.
摘要:
背景:对日本临床肿瘤学会2023年止吐临床实践指南进行了广泛修订,以反映抗肿瘤药的最新进展,止吐药,和抗肿瘤治疗方案.这一更新为止吐方案的疗效提供了新的证据。
方法:在2017年《Minds临床实践指南开发手册》的指导下,采用了严格的方法来更新指南;从1990年1月1日至2020年12月31日进行了全面的文献检索。
结果:综合过程导致创建了13个背景问题(BQ),12个临床问题(CQ),和三个未来的研究问题(FQs)。此外,还更新了呕吐风险分类.
结论:本指南的主要目标是提供全面的信息并促进知情决策,关于止吐治疗,患者和医疗保健提供者。
公众号